What is Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?

Category: Prescription Drugs

false

See also: Bortezomib Cyclophosphamide

Bortezomib-cyclophosphamide-dexamethasone, also known as VCd or CyBorD, is a regimen that may be used for the treatment of multiple myeloma. It contains the anticancer agents bortezomib and cyclophosphamide along with dexamethasone, a corticosteroid.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 9
Moderate 16
Mild 9
None 4

Commonly reported side effects and conditions associated with Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Side effect Patients
Peripheral neuropathy 6
Fatigue 5
Constant tiredness 2
Numbness 2
Tiredness 2
Bone pain 1

Show all 27 reported side effects

Dosages

Based on patients currently taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Dosage Patients
weekly 2
every 3 weeks 1
every other week 1
twice daily 1

Why patients stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Multiple reasons could be selected

Reason Patients
Course of treatment ended 15
Did not seem to work 3
Doctor's advice 3
Side effects too severe 3
See all 21 patients who've stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Duration

Currently taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Duration Patients
1 - 2 years 3
2 - 5 years 6

Stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Duration Patients
Less than 1 month 3
1 - 6 months 10
6 months - 1 year 6
1 - 2 years 2
Adherence
Adherence Evaluations
Always 31
Usually 5
Sometimes 0
Never taken as prescribed 2
Burden
Burden Evaluations
Very hard to take 2
Somewhat hard to take 10
A little hard to take 12
Not at all hard to take 14
Cost per month
Cost per month Evaluations
$200+ 12
$100-199 1
$50-99 0
$25-49 3
< $25 6
Not specified 16

What people switch to and from

Patients started taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD) after stopping:

Treatment Patients
Bortezomib (Velcade) 1
Lenalidomide (Revlimid) 1

Patients stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD) and switched to:

Treatment Patients
Lenalidomide-dexamethasone (Rd) 5
Bortezomib (Velcade) 2
Bortezomib-lenalidomide-dexamethasone (VRd) 1
Carfilzomib-lenalidomide-dexamethasone 1
Last updated:
There are no evaluations for Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD).